Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
Authors: Umapathysivam Mahesh M , Araldi Elisa , Hastoy Benoit , Dawed Adem Y , Vatandaslar Hasan , Sengupta Shahana , Kaufmann Adrian , Thomsen Søren , Hartmann Bolette , Jonsson Anna E , Kabakci Hasan , Thaman Swaraj , Grarup Niels , Have Christian T , Færch Kristine , Gjesing Anette P , Nawaz Sameena , Cheeseman Jane , Neville Matthew J , Pedersen Oluf , Walker Mark , Jennison Christopher , Hattersley Andrew T , Hansen Torben , Karpe Fredrik , Holst Jens J , Jones Angus G , Ristow Michael , McCarthy Mark I , Pearson Ewan R , Stoffel Markus , Gloyn Anna L 
Published: April 2023

Patients with type 2 diabetes vary in their response to currently available therapeutic agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control and increased risk of complications. We show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase(PAM),as well asPam-knockout mice, display increased resistance to GLP-1in vivo.Paminactivation in mice leads to reduced gastric GLP-1R expression and faster gastric emptying: this persists during GLP-1R agonist treatment and is rescued when GLP-1R activity is antagonized, indicating resistance to GLP-1’s gastric slowing properties. Meta-analysis of human data from studies examining GLP-1R agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphicPAMalleles p.S539W and p.D536G treated with GLP-1R agonist. Genetic variation inPAMhas effects on incretin signaling that alters response to medication used commonly for treatment of T2D.

(Funded by the Wellcome, Medical Research Council, European Union, NIHR Oxford Biomedical Research Centre, United Kingdom, Registered on ClinicalTrials.gov,NCT02723110.)

Summary Paragraph

Type 2 diabetes (T2D) is a leading cause of morbidity and mortality globally1. Current management of T2D patients focuses on lowering glycemic exposure and reducing complications with lifestyle and pharmacological interventions2. Despite the availability of multiple medications to lower glycated hemoglobin (HbA1c), only 53% of individuals with T2D reach the glycemic target (HbA1c <7%)3, 4. There is potential to improve medication selection through “precision medicine” where patient specific factors (e.g. genetic markers) are used to indicate whether a patient is more or less likely to respond to a medication. Here we show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase(PAM),as well asPam-knockout mice, have reduced PAM enzyme activity, display increased resistance to glucagon like peptide 1 (GLP-1)in vivoand have reduced response to the GLP-1 receptor agonist. Meta-analysis of human data from studies examining GLP-1 receptor agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphicPAMalleles p.S539W and p.D536G treated with GLP-1 receptor agonist. Genetic variation inPAMhas effects on incretin signaling that alters response to medication used commonly for treatment of T2D.